{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:51:39Z","timestamp":1784263899018,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>V-domain Ig suppressor of T-cell activation (VISTA), which mediates immune evasion in cancer, is mainly expressed on hematopoietic cells and myeloid cells in the tumor. We evaluated correlations among the expression of VISTA, the myeloid-derived suppressor cell marker CD33, and programmed death-1 (PD-1), and determined their relationships with clinicopathological characteristics and disease outcomes in melanoma. Diagnostic tissue from 136 cases of melanoma was evaluated by immunohistochemistry for CD33, VISTA, and PD-1 expression. Dual immunofluorescence using CD33 and VISTA antibodies was performed. VISTA expression positively correlated with CD33 expression in melanoma tissue. Dual immunofluorescence staining revealed that VISTA was expressed by CD33-positive myeloid cells. PD-1 expression correlated with CD33 and VISTA expression. CD33 and VISTA expression were significantly associated with negative prognostic factors, including a deeper Breslow thickness and an advanced stage of disease. High expression of either CD33 or VISTA was associated with worse survival. Positivity for both VISTA and PD-1 predicted worse survival. Multivariate analysis showed that both CD33 and VISTA expression were independent prognostic factors in cutaneous melanoma. VISTA and CD33 expression are independent unfavourable prognostic factors in melanoma, which suggests their potential as therapeutic targets.<\/jats:p>","DOI":"10.1038\/s41598-020-71216-2","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T10:02:31Z","timestamp":1598954551000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["The prognostic significance of VISTA and CD33-positive myeloid cells in cutaneous melanoma and their relationship with PD-1 expression"],"prefix":"10.1038","volume":"10","author":[{"given":"Jae Won","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Jae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung A.","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong Hyun","family":"Won","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Woo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Ho","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Eun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"key":"71216_CR1","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3109\/08820139.2012.673191","volume":"41","author":"NR Monu","year":"2012","unstructured":"Monu, N. R. & Frey, A. B. Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship. Immunol. Invest. 41, 595\u2013613 (2012).","journal-title":"Immunol. Invest."},{"key":"71216_CR2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3109\/08820139.2012.680635","volume":"41","author":"LA Haile","year":"2012","unstructured":"Haile, L. A., Greten, T. F. & Korangy, F. Immune suppression: the hallmark of myeloid derived suppressor cells. Immunol. Invest. 41, 581\u2013594 (2012).","journal-title":"Immunol. Invest."},{"key":"71216_CR3","doi-asserted-by":"crossref","first-page":"923","DOI":"10.4161\/cbt.11.11.15541","volume":"11","author":"A Romano","year":"2011","unstructured":"Romano, A., Vetro, C. & Adriani, M. Advances in understanding regulatory myeloid cells. Cancer Biol. Ther. 11, 923\u2013926 (2011).","journal-title":"Cancer Biol. Ther."},{"key":"71216_CR4","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1365-3083.2010.02463.x","volume":"72","author":"MK Brimnes","year":"2010","unstructured":"Brimnes, M. K. et al. Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR-\/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand. J. Immunol. 72, 540\u2013547 (2010).","journal-title":"Scand. J. Immunol."},{"key":"71216_CR5","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s00262-015-1765-6","volume":"64","author":"H Zhang","year":"2015","unstructured":"Zhang, H. et al. Myeloid-derived suppressor cells inhibit T cell proliferation in human extranodal NK\/T cell lymphoma: a novel prognostic indicator. Cancer Immunol. Immunother. 64, 1587\u20131599 (2015).","journal-title":"Cancer Immunol. Immunother."},{"key":"71216_CR6","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1158\/0008-5472.CAN-13-0305","volume":"73","author":"A Sawant","year":"2013","unstructured":"Sawant, A. & Ponnazhagan, S. Myeloid-derived suppressor cells as osteoclast progenitors: a novel target for controlling osteolytic bone metastasis. Cancer Res. 73, 4606\u20134610 (2013).","journal-title":"Cancer Res."},{"key":"71216_CR7","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.4049\/jimmunol.1202702","volume":"191","author":"Z Husain","year":"2013","unstructured":"Husain, Z., Huang, Y., Seth, P. & Sukhatme, V. P. Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. J. Immunol. 191, 1486\u20131495 (2013).","journal-title":"J. Immunol."},{"key":"71216_CR8","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1128\/JVI.01759-12","volume":"87","author":"A Qin","year":"2013","unstructured":"Qin, A. et al. Expansion of monocytic myeloid-derived suppressor cells dampens T cell function in HIV-1-seropositive individuals. J. Virol. 87, 1477\u20131490 (2013).","journal-title":"J. Virol."},{"key":"71216_CR9","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.4049\/jimmunol.1100660","volume":"187","author":"DB Flies","year":"2011","unstructured":"Flies, D. B., Wang, S., Xu, H. & Chen, L. Cutting edge: a monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models. J. Immunol. 187, 1537\u20131541 (2011).","journal-title":"J. Immunol."},{"key":"71216_CR10","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1158\/0008-5472.CAN-13-1506","volume":"74","author":"I Le Mercier","year":"2014","unstructured":"Le Mercier, I. et al. VISTA regulates the development of protective antitumor immunity. Cancer Res. 74, 1933\u20131944 (2014).","journal-title":"Cancer Res."},{"key":"71216_CR11","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1084\/jem.20100619","volume":"208","author":"L Wang","year":"2011","unstructured":"Wang, L. et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J. Exp. Med. 208, 577\u2013592 (2011).","journal-title":"J. Exp. Med."},{"key":"71216_CR12","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1172\/JCI74589","volume":"124","author":"DB Flies","year":"2014","unstructured":"Flies, D. B. et al. Coinhibitory receptor PD-1H preferentially suppresses CD4+ T cell-mediated immunity. J. Clin. Invest. 124, 1966\u20131975 (2014).","journal-title":"J. Clin. Invest."},{"key":"71216_CR13","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian, S. L., Drake, C. G. & Pardoll, D. M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450\u2013461 (2015).","journal-title":"Cancer Cell"},{"key":"71216_CR14","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1158\/2326-6066.CIR-14-0072","volume":"2","author":"JL Lines","year":"2014","unstructured":"Lines, J. L., Sempere, L. F., Broughton, T., Wang, L. & Noelle, R. VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy. Cancer Immunol. Res. 2, 510\u2013517 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"71216_CR15","doi-asserted-by":"crossref","first-page":"e109103","DOI":"10.1371\/journal.pone.0109103","volume":"9","author":"P Bharaj","year":"2014","unstructured":"Bharaj, P. et al. Characterization of programmed death-1 homologue-1 (PD-1H) expression and function in normal and HIV infected individuals. PLoS ONE 9, e109103 (2014).","journal-title":"PLoS ONE"},{"key":"71216_CR16","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00262-014-1643-7","volume":"64","author":"BP Kloke","year":"2015","unstructured":"Kloke, B. P. et al. Cancer immunotherapy achieves breakthrough status: 12th annual meeting of the association for cancer immunotherapy (CIMT), Mainz, Germany, May 6\u20138, 2014. Cancer Immunol. Immunother. 64, 923\u2013930 (2015).","journal-title":"Cancer Immunol. Immunother."},{"key":"71216_CR17","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.3389\/fimmu.2018.01310","volume":"9","author":"R Weber","year":"2018","unstructured":"Weber, R. et al. Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors. Front. Immunol. 9, 1310 (2018).","journal-title":"Front. Immunol."},{"key":"71216_CR18","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1158\/2326-6066.CIR-19-0008","volume":"7","author":"A Holtzhausen","year":"2019","unstructured":"Holtzhausen, A. et al. TAM family receptor kinase inhibition reverses MDSC-mediated suppression and augments anti-PD-1 therapy in melanoma. Cancer Immunol. Res. 7, 1672\u20131686 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"71216_CR19","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1158\/1078-0432.CCR-17-2542","volume":"24","author":"F Villarroel-Espindola","year":"2018","unstructured":"Villarroel-Espindola, F. et al. Spatially resolved and quantitative analysis of VISTA\/PD-1H as a novel immunotherapy target in human non-small cell lung cancer. Clin. Cancer Res. 24, 1562\u20131573 (2018).","journal-title":"Clin. Cancer Res."},{"key":"71216_CR20","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00262-017-1968-0","volume":"66","author":"L Wu","year":"2017","unstructured":"Wu, L. et al. Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma. Cancer Immunol. Immunother. 66, 627\u2013636 (2017).","journal-title":"Cancer Immunol. Immunother."},{"key":"71216_CR21","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00262-018-2169-1","volume":"67","author":"LF Kuklinski","year":"2018","unstructured":"Kuklinski, L. F. et al. VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival. Cancer Immunol. Immunother. 67, 1113\u20131121 (2018).","journal-title":"Cancer Immunol. Immunother."},{"key":"71216_CR22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","volume":"18","author":"S Qin","year":"2019","unstructured":"Qin, S. et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol. Cancer 18, 155 (2019).","journal-title":"Mol. Cancer"},{"key":"71216_CR23","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3322\/caac.21409","volume":"67","author":"JE Rshenwald","year":"2017","unstructured":"Rshenwald, J. E. et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer. J. Clin. 67, 472\u2013492 (2017).","journal-title":"CA Cancer. J. Clin."},{"key":"71216_CR24","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1200\/JCO.2015.61.1509","volume":"33","author":"RL Ferris","year":"2015","unstructured":"Ferris, R. L. Immunology and immunotherapy of head and neck cancer. J. Clin. Oncol. 33, 3293\u20133304 (2015).","journal-title":"J. Clin. Oncol."},{"key":"71216_CR25","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00262-011-1154-8","volume":"61","author":"AM De Costa","year":"2012","unstructured":"De Costa, A. M., Schuyler, C. A., Walker, D. D. & Young, M. R. Characterization of the evolution of immune phenotype during the development and progression of squamous cell carcinoma of the head and neck. Cancer Immunol. Immunother. 61, 927\u2013939 (2012).","journal-title":"Cancer Immunol. Immunother."},{"key":"71216_CR26","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3389\/fimmu.2014.00387","volume":"5","author":"S Gantt","year":"2014","unstructured":"Gantt, S., Gervassi, A., Jaspan, H. & Horton, H. The role of myeloid-derived suppressor cells in immune ontogeny. Front. Immunol. 5, 387 (2014).","journal-title":"Front. Immunol."},{"key":"71216_CR27","doi-asserted-by":"crossref","first-page":"e26967","DOI":"10.4161\/onci.26967","volume":"2","author":"D Chandra","year":"2013","unstructured":"Chandra, D. & Gravekamp, C. Myeloid-derived suppressor cells: cellular missiles to target tumors. Oncoimmunology 2, e26967 (2013).","journal-title":"Oncoimmunology"},{"key":"71216_CR28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.semcancer.2013.02.007","volume":"23","author":"S Brandau","year":"2013","unstructured":"Brandau, S., Moses, K. & Lang, S. The kinship of neutrophils and granulocytic myeloid-derived suppressor cells in cancer: cousins, siblings or twins?. Semin. Cancer Biol. 23, 171\u2013182 (2013).","journal-title":"Semin. Cancer Biol."},{"key":"71216_CR29","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.semcancer.2012.01.011","volume":"22","author":"S Ostrand-Rosenberg","year":"2012","unstructured":"Ostrand-Rosenberg, S., Sinha, P., Beury, D. W. & Clements, V. K. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin. Cancer Biol. 22, 275\u2013281 (2012).","journal-title":"Semin. Cancer Biol."},{"key":"71216_CR30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00262-011-1161-9","volume":"61","author":"P Filipazzi","year":"2012","unstructured":"Filipazzi, P., Huber, V. & Rivoltini, L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol. Immunother. 61, 255\u2013263 (2012).","journal-title":"Cancer Immunol. Immunother."},{"key":"71216_CR31","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.4049\/jimmunol.0802740","volume":"182","author":"S Ostrand-Rosenberg","year":"2009","unstructured":"Ostrand-Rosenberg, S. & Sinha, P. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 182, 4499\u20134506 (2009).","journal-title":"J. Immunol."},{"key":"71216_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2015.10.009","volume":"39","author":"DH Munn","year":"2016","unstructured":"Munn, D. H. & Bronte, V. Immune suppressive mechanisms in the tumor microenvironment. Curr. Opin. Immunol. 39, 1\u20136 (2016).","journal-title":"Curr. Opin. Immunol."},{"key":"71216_CR33","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20131916","volume":"211","author":"MZ Noman","year":"2014","unstructured":"Noman, M. Z. et al. PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J. Exp. Med. 211, 781\u2013790 (2014).","journal-title":"J. Exp. Med."},{"key":"71216_CR34","doi-asserted-by":"crossref","first-page":"e1008371","DOI":"10.1080\/2162402X.2015.1008371","volume":"4","author":"K Ridder","year":"2015","unstructured":"Ridder, K. et al. Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment. Oncoimmunology 4, e1008371 (2015).","journal-title":"Oncoimmunology"},{"key":"71216_CR35","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4062\/biomolther.2018.201","volume":"27","author":"S Nam","year":"2019","unstructured":"Nam, S., Lee, A., Lim, J. & Lim, J. S. Analysis of the expression and regulation of PD-1 protein on the surface of myeloid-derived suppressor cells (MDSCs). Biomol. Ther. (Seoul) 27, 63\u201370 (2019).","journal-title":"Biomol. Ther. (Seoul)"},{"key":"71216_CR36","first-page":"1378","volume":"130","author":"J Boyd-Kirkup","year":"2017","unstructured":"Boyd-Kirkup, J. et al. HMBD004, a novel anti-CD47xCD33 bispecific antibody displays potent anti-tumor effects in pre-clinical models of AML. Blood 130, 1378\u20131378 (2017).","journal-title":"Blood"},{"key":"71216_CR37","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.blre.2014.04.001","volume":"28","author":"GS Laszlo","year":"2014","unstructured":"Laszlo, G. S., Estey, E. H. & Walter, R. B. The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev. 28, 143\u2013153 (2014).","journal-title":"Blood Rev."},{"key":"71216_CR38","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1189\/jlb.0205096","volume":"79","author":"T Hernandez-Caselles","year":"2006","unstructured":"Hernandez-Caselles, T. et al. A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing. J. Leukoc. Biol. 79, 46\u201358 (2006).","journal-title":"J. Leukoc. Biol."},{"key":"71216_CR39","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1182\/blood.V92.9.3203","volume":"92","author":"MN Dworzak","year":"1998","unstructured":"Dworzak, M. N., Fritsch, G., Froschl, G., Printz, D. & Gadner, H. Four-color flow cytometric investigation of terminal deoxynucleotidyl transferase-positive lymphoid precursors in pediatric bone marrow: CD79a expression precedes CD19 in early B-cell ontogeny. Blood 92, 3203\u20133209 (1998).","journal-title":"Blood"},{"key":"71216_CR40","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1200\/JCO.1991.9.3.478","volume":"9","author":"DA Scheinberg","year":"1991","unstructured":"Scheinberg, D. A. et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J. Clin. Oncol. 9, 478\u2013490 (1991).","journal-title":"J. Clin. Oncol."},{"key":"71216_CR41","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1200\/JCO.1993.11.2.294","volume":"11","author":"MA Schwartz","year":"1993","unstructured":"Schwartz, M. A. et al. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J. Clin. Oncol. 11, 294\u2013303 (1993).","journal-title":"J. Clin. Oncol."},{"key":"71216_CR42","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood.V100.4.1233.h81602001233_1233_1239","volume":"100","author":"JG Jurcic","year":"2002","unstructured":"Jurcic, J. G. et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 100, 1233\u20131239 (2002).","journal-title":"Blood"},{"key":"71216_CR43","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13045-020-00917-y","volume":"13","author":"X Huang","year":"2020","unstructured":"Huang, X. et al. VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy. J. Hematol. Oncol. 13, 83 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"71216_CR44","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.1420370112","volume":"112","author":"J Liu","year":"2015","unstructured":"Liu, J. et al. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proc. Natl. Acad. Sci. U. S. A. 112, 6682\u20136687 (2015).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"71216_CR45","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/modpathol.2017.89","volume":"30","author":"H Kakavand","year":"2017","unstructured":"Kakavand, H. et al. Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. Mod. Pathol. 30, 1666\u20131676 (2017).","journal-title":"Mod. Pathol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71216-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71216-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71216-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T17:51:12Z","timestamp":1670349072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71216-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["71216"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-71216-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,1]]},"assertion":[{"value":"13 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14372"}}